Myriad Genetics, Inc. (MYGN)
USD 13.25
(-4.12%)
USD 13.25
(-4.12%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -112 Million USD | -311.76% |
| 2021 | -27.2 Million USD | 87.84% |
| 2020 | -223.7 Million USD | -4963.04% |
| 2019 | 4.6 Million USD | 0.0% |
| 2018 | 4.6 Million USD | -96.49% |
| 2017 | 131 Million USD | 500.92% |
| 2016 | 21.8 Million USD | -82.6% |
| 2015 | 125.3 Million USD | 56.23% |
| 2014 | 80.2 Million USD | -54.49% |
| 2013 | 176.22 Million USD | 19.77% |
| 2012 | 147.13 Million USD | 31.2% |
| 2011 | 112.15 Million USD | 11.36% |
| 2010 | 100.71 Million USD | -33.88% |
| 2009 | 152.3 Million USD | 80.0% |
| 2008 | 84.61 Million USD | 76.85% |
| 2007 | 47.84 Million USD | 236.85% |
| 2006 | -34.96 Million USD | 8.45% |
| 2005 | -38.18 Million USD | 4.47% |
| 2004 | -39.97 Million USD | 1.58% |
| 2003 | -40.62 Million USD | -63.63% |
| 2002 | -24.82 Million USD | -77.46% |
| 2001 | -13.98 Million USD | -94.99% |
| 2000 | -7.17 Million USD | 17.74% |
| 1999 | -8.72 Million USD | 12.78% |
| 1998 | -10 Million USD | -2.04% |
| 1997 | -9.8 Million USD | -6.52% |
| 1996 | -9.2 Million USD | -55.93% |
| 1995 | -5.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | -116.1 Million USD | -112.25% |
| 2023 Q1 | -54.7 Million USD | -29.31% |
| 2023 Q3 | -61.3 Million USD | 47.2% |
| 2022 Q3 | -35.1 Million USD | -148.94% |
| 2022 Q2 | -14.1 Million USD | 31.22% |
| 2022 Q4 | -42.3 Million USD | -20.51% |
| 2022 Q1 | -20.5 Million USD | -169.74% |
| 2022 FY | -112 Million USD | -311.76% |
| 2021 Q3 | 24.6 Million USD | 623.4% |
| 2021 FY | -27.2 Million USD | 87.84% |
| 2021 Q2 | -4.7 Million USD | 88.1% |
| 2021 Q1 | -39.5 Million USD | 10.63% |
| 2021 Q4 | -7.6 Million USD | -130.89% |
| 2020 Q2 | -55.4 Million USD | 51.91% |
| 2020 FY | -223.7 Million USD | -4963.04% |
| 2020 Q3 | -15.2 Million USD | 72.56% |
| 2020 Q4 | -44.2 Million USD | -190.79% |
| 2020 Q1 | -115.2 Million USD | -1287.95% |
| 2019 Q3 | -20.6 Million USD | -390.48% |
| 2019 FY | 4.6 Million USD | 0.0% |
| 2019 Q1 | 6.9 Million USD | 165.38% |
| 2019 Q4 | -8.3 Million USD | 59.71% |
| 2019 Q2 | -4.2 Million USD | -160.87% |
| 2018 Q1 | 11.4 Million USD | -64.49% |
| 2018 FY | 4.6 Million USD | -96.49% |
| 2018 Q2 | 13.1 Million USD | 14.91% |
| 2018 Q3 | -700 Thousand USD | -105.34% |
| 2018 Q4 | 2.6 Million USD | 471.43% |
| 2017 Q1 | 4.2 Million USD | -28.81% |
| 2017 FY | 131 Million USD | 500.92% |
| 2017 Q4 | 32.1 Million USD | -60.42% |
| 2017 Q3 | 81.1 Million USD | 528.68% |
| 2017 Q2 | 12.9 Million USD | 207.14% |
| 2016 FY | 21.8 Million USD | -82.6% |
| 2016 Q2 | 23.4 Million USD | -28.22% |
| 2016 Q3 | -1.2 Million USD | -105.13% |
| 2016 Q4 | 5.9 Million USD | 591.67% |
| 2016 Q1 | 32.6 Million USD | 7.59% |
| 2015 FY | 125.3 Million USD | 56.23% |
| 2015 Q3 | 26.6 Million USD | 42.25% |
| 2015 Q4 | 30.3 Million USD | 13.91% |
| 2015 Q2 | 18.7 Million USD | -12.92% |
| 2015 Q1 | 21.47 Million USD | -10.64% |
| 2014 Q3 | 15.98 Million USD | -52.48% |
| 2014 Q4 | 24.03 Million USD | 50.36% |
| 2014 Q1 | 36.77 Million USD | -26.99% |
| 2014 FY | 80.2 Million USD | -54.49% |
| 2014 Q2 | 33.62 Million USD | -8.54% |
| 2013 Q2 | 44.07 Million USD | 16.32% |
| 2013 Q3 | 55.46 Million USD | 25.84% |
| 2013 Q4 | 50.36 Million USD | -9.2% |
| 2013 FY | 176.22 Million USD | 19.77% |
| 2013 Q1 | 37.89 Million USD | 8.15% |
| 2012 FY | 147.13 Million USD | 31.2% |
| 2012 Q1 | 29.61 Million USD | 4.66% |
| 2012 Q2 | 29.14 Million USD | -1.6% |
| 2012 Q3 | 30.13 Million USD | 3.41% |
| 2012 Q4 | 35.03 Million USD | 16.26% |
| 2011 Q4 | 28.29 Million USD | 12.74% |
| 2011 Q1 | 27.94 Million USD | 15.5% |
| 2011 FY | 112.15 Million USD | 11.36% |
| 2011 Q3 | 25.09 Million USD | -3.61% |
| 2011 Q2 | 26.04 Million USD | -6.8% |
| 2010 FY | 100.71 Million USD | -33.88% |
| 2010 Q4 | 24.19 Million USD | 7.33% |
| 2010 Q3 | 22.53 Million USD | -57.68% |
| 2010 Q2 | 53.25 Million USD | 60.15% |
| 2010 Q1 | 33.25 Million USD | -5.96% |
| 2009 FY | 152.3 Million USD | 80.0% |
| 2009 Q1 | 25.31 Million USD | 19.41% |
| 2009 Q3 | 30.44 Million USD | 28.77% |
| 2009 Q2 | 23.64 Million USD | -6.63% |
| 2009 Q4 | 35.35 Million USD | 16.15% |
| 2008 Q3 | 14.45 Million USD | -77.95% |
| 2008 FY | 84.61 Million USD | 76.85% |
| 2008 Q4 | 21.2 Million USD | 46.69% |
| 2008 Q2 | 65.54 Million USD | 1515.27% |
| 2008 Q1 | -4.63 Million USD | 8.6% |
| 2007 FY | 47.84 Million USD | 236.85% |
| 2007 Q4 | -5.06 Million USD | 36.65% |
| 2007 Q3 | -7.99 Million USD | -2.5% |
| 2007 Q2 | -7.8 Million USD | -31.45% |
| 2007 Q1 | -5.93 Million USD | 32.5% |
| 2006 FY | -34.96 Million USD | 8.45% |
| 2006 Q2 | -11.42 Million USD | -19.36% |
| 2006 Q1 | -9.57 Million USD | -20.36% |
| 2006 Q3 | -12.42 Million USD | -8.76% |
| 2006 Q4 | -8.79 Million USD | 29.21% |
| 2005 Q4 | -7.95 Million USD | 13.96% |
| 2005 FY | -38.18 Million USD | 4.47% |
| 2005 Q3 | -9.24 Million USD | 7.13% |
| 2005 Q2 | -9.95 Million USD | 0.34% |
| 2005 Q1 | -9.98 Million USD | 0.62% |
| 2004 Q2 | -10.46 Million USD | 2.2% |
| 2004 Q1 | -10.69 Million USD | -8.54% |
| 2004 Q4 | -10.04 Million USD | -0.56% |
| 2004 Q3 | -9.99 Million USD | 4.48% |
| 2004 FY | -39.97 Million USD | 1.58% |
| 2003 Q2 | -7.08 Million USD | -27.95% |
| 2003 Q3 | -9.6 Million USD | -35.7% |
| 2003 Q4 | -9.85 Million USD | -2.55% |
| 2003 FY | -40.62 Million USD | -63.63% |
| 2003 Q1 | -5.53 Million USD | 19.73% |
| 2002 Q4 | -6.89 Million USD | -29.68% |
| 2002 FY | -24.82 Million USD | -77.46% |
| 2002 Q1 | -3.49 Million USD | -42.15% |
| 2002 Q2 | -6.84 Million USD | -95.87% |
| 2002 Q3 | -5.31 Million USD | 22.37% |
| 2001 Q4 | -2.45 Million USD | -107.55% |
| 2001 Q3 | -1.18 Million USD | 45.8% |
| 2001 Q1 | -1.72 Million USD | -45.28% |
| 2001 Q2 | -2.18 Million USD | -26.53% |
| 2001 FY | -13.98 Million USD | -94.99% |
| 2000 Q1 | -2.09 Million USD | -10.0% |
| 2000 Q2 | -2.56 Million USD | -22.68% |
| 2000 FY | -7.17 Million USD | 17.74% |
| 2000 Q3 | -2.07 Million USD | 19.25% |
| 2000 Q4 | -1.18 Million USD | 42.55% |
| 1999 Q2 | -2.3 Million USD | -4.55% |
| 1999 Q1 | -2.2 Million USD | 24.14% |
| 1999 Q4 | -1.9 Million USD | 13.64% |
| 1999 FY | -8.72 Million USD | 12.78% |
| 1999 Q3 | -2.2 Million USD | 4.35% |
| 1998 Q4 | -2.9 Million USD | -7.41% |
| 1998 FY | -10 Million USD | -2.04% |
| 1998 Q2 | -3.1 Million USD | -19.23% |
| 1998 Q3 | -2.7 Million USD | 12.9% |
| 1998 Q1 | -2.6 Million USD | -13.04% |
| 1997 Q4 | -2.3 Million USD | -27.78% |
| 1997 Q2 | 300 Thousand USD | 109.38% |
| 1997 Q3 | -1.8 Million USD | -700.0% |
| 1997 FY | -9.8 Million USD | -6.52% |
| 1997 Q1 | -3.2 Million USD | 8.57% |
| 1996 Q1 | -1.8 Million USD | -157.14% |
| 1996 FY | -9.2 Million USD | -55.93% |
| 1996 Q2 | -1.9 Million USD | -5.56% |
| 1996 Q3 | -2.8 Million USD | -47.37% |
| 1996 Q4 | -3.5 Million USD | -25.0% |
| 1995 Q4 | -700 Thousand USD | 56.25% |
| 1995 FY | -5.9 Million USD | 0.0% |
| 1995 Q3 | -1.6 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 51.827% |
| Prenetics Global Limited | -62.72 Million USD | -78.56% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -7135.142% |
| CareDx, Inc | -190.28 Million USD | 41.141% |
| Exact Sciences Corporation | -204.14 Million USD | 45.138% |
| Exagen Inc. | -23.68 Million USD | -372.793% |
| Inotiv, Inc. | -105.14 Million USD | -6.525% |
| Guardant Health, Inc. | -479.44 Million USD | 76.64% |
| Biodesix, Inc. | -52.14 Million USD | -114.782% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -4160.105% |
| Precipio, Inc. | -5.85 Million USD | -1813.549% |
| iSpecimen Inc. | -11.09 Million USD | -909.056% |
| Natera, Inc. | -434.8 Million USD | 74.241% |
| Aspira Women's Health Inc. | -16.69 Million USD | -571.061% |
| Standard BioTools Inc. | -74.65 Million USD | -50.021% |
| 23andMe Holding Co. | -666.7 Million USD | 83.201% |
| Castle Biosciences, Inc. | -57.46 Million USD | -94.898% |
| Personalis, Inc. | -108.29 Million USD | -3.42% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -26.581% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -1025.961% |
| OpGen, Inc. | -32.66 Million USD | -242.838% |
| T2 Biosystems, Inc. | -50.07 Million USD | -123.656% |
| ICON Public Limited Company | 612.33 Million USD | 118.291% |
| NeoGenomics, Inc. | -87.96 Million USD | -27.319% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -7135.142% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 113.254% |
| RadNet, Inc. | 3.04 Million USD | 3779.369% |
| MDxHealth SA | -43.1 Million USD | -159.861% |
| Psychemedics Corporation | -4.15 Million USD | -2596.196% |
| Illumina, Inc. | -1.16 Billion USD | 90.353% |
| Check-Cap Ltd. | -17.56 Million USD | -537.523% |
| Twist Bioscience Corporation | -208.72 Million USD | 46.341% |
| DarioHealth Corp. | -59.42 Million USD | -88.467% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 33.264% |
| Sera Prognostics, Inc. | -36.24 Million USD | -209.034% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -1013.292% |
| OPKO Health, Inc. | -188.86 Million USD | 40.698% |
| Medpace Holdings, Inc. | 282.81 Million USD | 139.603% |
| Neogen Corporation | -9.42 Million USD | -1088.833% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -1002.714% |
| Prenetics Global Limited | -62.72 Million USD | -78.56% |
| Mainz Biomed B.V. | -26.29 Million USD | -325.925% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -1311.111% |
| Trinity Biotech plc | -24.01 Million USD | -366.317% |
| Neuronetics, Inc. | -30.18 Million USD | -270.996% |
| Sotera Health Company | 51.37 Million USD | 318.001% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -1311.111% |